Literature DB >> 9138724

Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome.

M Dierssen1, I F Vallina, C Baamonde, S García-Calatayud, M A Lumbreras, J Flórez.   

Abstract

Mice with segmental trisomy 16 (Ts65Dn) which have triplication of a region of mouse chromosome 16 homologous to the Down syndrome critical region in human chromosome 21, are used as a model for Down syndrome. Functioning of the central beta-noradrenergic transmission was studied in Ts65Dn mice. Binding analysis in cerebral cortex revealed no change in the number of beta-adrenoceptors and a slight reduction of affinity. The beta-adrenoceptor transduction was assessed by analyzing cAMP formation in the cerebral cortex, hippocampus and cerebellar cortex under basal conditions and after stimulation with isoprenaline and forskolin. Basal production of cAMP was significantly reduced in hippocampus and cerebellar cortex of Ts65Dn mice compared to control, but not in cerebellum. After phosphodiesterase inhibition, net increments in cAMP accumulation were similar in both groups of mice. Stimulation of cAMP production by isoprenaline (10 microM) and forskolin (10 microM) was much higher in hippocampus than in cerebral cortex of either group. In both areas, but not in cerebellum, the stimulatory responses were consistently and significantly smaller in Ts65Dn than in control mice. Concentration-response curves for isoprenaline and forskolin were generated in the cerebral cortex. Emax responses were lower in trisomic than in control mice; however, in Ts65Dn mice the slope of the response curve to isoprenaline was markedly depressed whereas that to forskolin was similar to control. It is concluded that Ts65Dn mice show severe deficiencies in the synaptic transmission of the central beta-noradrenergic system, which are selective for specific brain areas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138724     DOI: 10.1016/s0006-8993(96)01173-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

3.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

Review 4.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

5.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 6.  Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?

Authors:  Jennifer N K Nyarko; Maa O Quartey; Glen B Baker; Darrell D Mousseau
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

7.  Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation.

Authors:  Nadia Sahir; Douglas E Brenneman; Joanna M Hill
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

8.  Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling.

Authors:  Keith Schutsky; Ming Ouyang; Steven A Thomas
Journal:  Learn Mem       Date:  2011-08-30       Impact factor: 2.460

9.  Cardiac autonomic modulation of children with Down syndrome.

Authors:  Tatiana Dias de Carvalho; Luiz Carlos de Abreu; Zan Mustacchi; Luiz Carlos Marques Vanderlei; Moacir Fernandes Godoy; Rodrigo Daminello Raimundo; Celso Ferreira Filho; Talita Dias da Silva; Laura Guilhoto; Viviane Perico; Vivian Ribeiro Finotti; Celso Ferreira
Journal:  Pediatr Cardiol       Date:  2014-08-28       Impact factor: 1.655

10.  Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801.

Authors:  A Siddiqui; T Lacroix; M R Stasko; J J Scott-McKean; A C S Costa; K J Gardiner
Journal:  Genes Brain Behav       Date:  2008-10       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.